HC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Lowers Price Target to $13

Benzinga Newsdesk www.benzinga.com Negative 56.7%

Neg 56.7% Neu 0% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis maintains Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and lowers the price target from $32 to $13.